Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MabRella
NCT01987505Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2013
- Primary completion
- Apr 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rituximab in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL), sponsored by Roche. Primary endpoint: Percentage of Participants With Administration-Associated Reactions up to 32 months. Started Nov 2013; status: completed.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01987505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01987505.